Journal History
| 2013 | The inaugural issue was released. Biomedicines was published as a quarterly journal. |
| 2015 | Biomedicines established the following section:
|
| 2016 | Biomedicines was indexed in Emerging Sources Citation Index (ESCI) of the Web of Science. Biomedicines established the following section:
|
| 2017 | Biomedicines was indexed in Scopus (Elsevier), starting with Volume 1 (Issue 1). Biomedicines was indexed in PubMed—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). Biomedicines was indexed in PubMed Central (PMC)—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). Biomedicines starts the Travel Awards project. |
| 2018 | Biomedicines established the following section:
|
| 2019 | Biomedicines was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 5 (Issue 1). Biomedicines established the following sections:
- Nanotechnology and Biotechnology was renamed as Biomedical Materials and Nanomedicine; - Therapeutic Strategies in Different Diseases was renamed as Molecular and Translational Medicine; - Thrombosis and Hemostasis was discontinued; - Model Systems in Research and Development was discontinued; - Virology, Vaccines and Viral Vectors was discontinued; - Tumor Cell Biology was discontinued. |
| 2020 | Biomedicines adopted a monthly publication schedule. Biomedicines received its first Impact Factor (4.717), ranked 36/270 (Q1) in “Pharmacology & Pharmacy”, and ranked 30/138 (Q1) in “Medicine, Research & Experimental”. Biomedicines published its 1,000th paper. Biomedicines rearranges the following sections:
|
| 2021 | Biomedicines starts the Young Investigator Award project. Biomedicines organized the 1st International Electronic Conference on Biomedicine (ECB 2021). Biomedicines organized the First Canadian Peptide and Protein Community Virtual Symposium (CPPC 2021). Biomedicines received its 2020 Impact Factor (6.081), ranked 32/275 (Q1) in “Pharmacology & Pharmacy”, ranked 32/140 (Q1) in “Medicine, Research & Experimental”, and ranked 65/298 (Q1) in “Biochemistry & Molecular Biology”. Biomedicines rearranges the following sections:
- Biomedical Materials was merged with Biomedical Engineering in Human Health to create a new section Biomedical Engineering and Materials; - Cancer Biology and Therapeutics was renamed as Cancer Biology and Oncology; - Neurobiology and Neurologic Disease was renamed as Neurobiology and Clinical Neuroscience. |
| 2022 | Biomedicines announced the 2022 Early-Career Women Award/2022 Young Investigator Award. Biomedicines received its 2021 Impact Factor (4.757), ranked 87/279 (Q2) in “Pharmacology & Pharmacy”, ranked 62/139 (Q2) in “Medicine, Research & Experimental”, and ranked 121/297 (Q2) in “Biochemistry & Molecular Biology”. |
| 2023 | The year 2023 marked the 10th Anniversary of Biomedicines. Biomedicines received its 2022 Impact Factor (4.7), ranked 69/277 (Q1) in “Pharmacology & Pharmacy”, ranked 54/136 (Q2) in “Medicine, Research & Experimental”, and ranked 92/285 (Q2) in “Biochemistry & Molecular Biology”. Biomedicines announced the 2024 Travel Award/2022 Best Paper Award/2023 Outstanding Reviewer Award/2023 Young Investigator Award. |
| 2024 | Biomedicines rearranges the following sections:
|
Editor-in-Chief
| 2013–2016 | Editor-in-Chief: Prof. Dr. Kenneth Cornetta |
| 2016–2023 | Editor-in-Chief: Prof. Dr. Shaker A. Mousa |
| 2023–present | Editor-in-Chief: Prof. Dr. Felipe Fregni |
Section Editor-in-Chief
| 2016–2022 | Section Editor-in-Chief: Dr. Vincenzo Cerullo for the section on Tumor Immunology and Immunotherapy |
| 2016–present | Section Editor-in-Chief: Dr. Bruno Meloni for the section on Neurobiology and Clinical Neuroscience |
| 2019–present | Section Editor-in-Chief: Prof. Dr. Jun Lu for the section on Drug Discovery, Development and Delivery Section Editor-in-Chief: Dr. Veronique Baud for the section on Cancer Biology and Oncology |
| 2022–2024 | Section Editor-in-Chief: Prof. Dr. Robert Passier for the section on Biomedical Engineering in Human Health Section Editor-in-Chief: Prof. Dr. Manfredi Tesauro for the section on Endocrinology and Metabolism Research |
| 2022–present | Section Editor-in-Chief: Prof. Dr. Paul Rösch for the section on Cell Biology and Pathology Section Editor-in-Chief: Dr. Bernard Lebleu for the section on Gene and Cell Therapy |
| 2024–present | Section Editor-in-Chief: Prof. Dr. Stephen Riordan for the section on Molecular and Translational Medicine |
| 2025–present | Section Editor-in-Chief: Dr. Timo Gaber for the section on Immunology and Immunotherapy |
